A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

⟵ Back to Search Results

Beigene Study ID

AdvanTIG-302 BGB-A317-A1217-302

ClinicalTrials.gov ID

NCT04746924

Sex: All

Age: 18 Years and older (Adult, Older Adult)

No Study Documents

Locations

Sex: All

Age: 18 Years and older (Adult, Older Adult)

No Study Documents